Molecular Partners (NASDAQ:MOLN) Coverage Initiated by Analysts at Lifesci Capital

Lifesci Capital began coverage on shares of Molecular Partners (NASDAQ:MOLN) in a research note issued on Tuesday,Benzinga reports. The brokerage set an “outperform” rating and a $12.00 price target on the stock. Lifesci Capital’s target price suggests a potential upside of 171.19% from the stock’s current price.

Molecular Partners Stock Performance

Shares of NASDAQ:MOLN opened at $4.43 on Tuesday. The firm has a market cap of $178.61 million, a price-to-earnings ratio of -2.06 and a beta of 1.06. The business has a 50-day simple moving average of $5.09 and a two-hundred day simple moving average of $5.35. Molecular Partners has a fifty-two week low of $3.32 and a fifty-two week high of $12.70.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings data on Thursday, March 6th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative return on equity of 39.31%. As a group, research analysts predict that Molecular Partners will post -1.93 earnings per share for the current year.

Hedge Funds Weigh In On Molecular Partners

A hedge fund recently raised its stake in Molecular Partners stock. Suvretta Capital Management LLC lifted its stake in Molecular Partners AG (NASDAQ:MOLN) by 455.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,221,494 shares of the company’s stock after purchasing an additional 1,821,494 shares during the period. Suvretta Capital Management LLC owned 5.50% of Molecular Partners worth $10,548,000 at the end of the most recent reporting period. 26.55% of the stock is currently owned by institutional investors.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.